CompletedNot applicableNCT03561909
Kinetics of Blood Platelets Transfused to Healthy Subjects
Studying Fetal and neonatal alloimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prophylix Pharma AS
- Principal Investigator
- Jens Kjeldsen-Kragh, MD, PhDProphylix Pharma AS
- Intervention
- Platelet transfusion(other)
- Enrollment
- 25 enrolled
- Eligibility
- 18-50 years · MALE
- Timeline
- 2018 – 2018
Study locations (1)
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt am Main, Hessia, Germany
Collaborators
Larix A/S · Fraunhofer Institute for Translational Medicine and Pharmacology ITMP · Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen · Bioscientia Central Laboratory
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03561909 on ClinicalTrials.govOther trials for Fetal and neonatal alloimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06533098A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Janssen Research & Development, LLC
- RECRUITINGPHASE3NCT06449651A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Janssen Research & Development, LLC
- RECRUITINGNCT04598750The Neonatal Hemorrhagic Risk Assessment in ThrombocytopeniaKarolinska Institutet
See all trials for Fetal and neonatal alloimmune thrombocytopenia →